Severe left ventricular dysfunction and valvular heart disease: should we operate?

Similar documents
AS with reduced LV ejection fraction: Contractile reserve should be systematically assessed: PRO

Chronic Primary Mitral Regurgitation

ECHO HAWAII. Role of Stress Echo in Valvular Heart Disease. Not only ischemia! Cardiomyopathy. Prosthetic Valve. Diastolic Dysfunction

Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal

Aortic Stenosis Steven F. Bolling, M.D. Professor of Cardiac Surgery University of Michigan

Low Gradient Severe? AS

Mitral Valve prolapse: What s new? Which indications of early surgery? Input of new 2017 ESC/EACTS guidelines. Christophe Tribouilloy Amiens, France

How does Pulmonary Hypertension Affect the Decision to Intervene in Mitral Valve Disease? NO DISCLOSURE

Measuring the risk in valve patients Lessons learnt from the TAVI story? Bernard Iung Bichat Hospital, Paris, France

Minimally invasive therapies for the mitral valve: How will you incorporate into your clinical practice? Guilherme F.

Prof. Patrizio LANCELLOTTI, MD, PhD Heart Valve Clinic, University of Liège, CHU Sart Tilman, Liège, BELGIUM

Aortic Valve Stenosis: Flow and Gradient stratification and association with TAVR outcomes

Primary Mitral Valve Disease: Natural History & Triggers for Intervention ACC Latin American Conference 2017

Primary Mitral Regurgitation

A patient with aortic stenosis and LV dysfunction EuroECHO & Other Imaging Modalities 2012 Athens, Greece

VALVULAR HEART DISEASE AND PULMONARY CIRCULATION

Spotlight on Valvular Heart Disease Guidelines

Aortic Valve Stenosis: When stress TTE and/or TEE is required to make the diagnosis and guide treatment

Severe aortic stenosis should be operated before symptom onset CONTRA. Helmut Baumgartner

Understanding the guidelines for Interventions in MR. Ali AlMasood

Valvular Guidelines: The Past, the Present, the Future

Reshape/Coapt: do we need more? Prof. J Zamorano Head of Cardiology University Hospital Ramon y Cajal, Madrid

What the Cardiologist needs to know from Medical Images

Ann Thorac Cardiovasc Surg 2015; 21: Online April 18, 2014 doi: /atcs.oa Original Article

Valvular Intervention

Ischemic Mitral Valve Disease: Repair, Replace or Ignore?

Aortic Stenosis: UPDATE Anjan Sinha, MD Krannert Institute of Cardiology

Aortic stenosis aetiology: morphology of calcific AS,

Management of Tricuspid Regurgitation

Management of significant asymptomatic aortic stenosis. Alec Vahanian Bichat Hospital University Paris VII Paris, France

Aortic valve implantation using the femoral and apical access: a single center experience.

Advanced Evaluation of Left Ventricular Function in Degenerative MR. Dr Julien Magne, PhD University of Liege, CHU Sart Tilman, Liege, Belgium

Asymptomatic Valvular Disease:

Load and Function - Valvular Heart Disease. Tom Marwick, Cardiovascular Imaging Cleveland Clinic

Reverse left atrium and left ventricle remodeling after aortic valve interventions

A Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision

Percutaneous Mitral Valve Repair: What Can We Treat and What Should We Treat

Aortic valve Stenosis: Insights in the evaluation of LV function. Erwan DONAL Cardiologie CHU Rennes

Sténose aortique à Bas Débit et Bas Gradient

Bicuspid aortic root spared during ascending aorta surgery: an update of long-term results

Mitral Valve Disease, When to Intervene

When is it too late to perform transcatheter mitral valve repair? Alec Vahanian, FESC,FRCP(Edin.) Bichat hospital University Paris VII

PERCUTANEOUS MITRAL VALVE THERAPIES 13 TH ANNUAL CARDIAC, VASCULAR AND STROKE CARE CONFERENCE PIEDMONT ATHENS REGIONAL

«Paradoxical» low-flow, low-gradient AS with preserved LV function: A Silent Killer

Disclosures. ESC Munich 2012 Bernard Iung, MD Consultancy: Abbott Boehringer Ingelheim Bayer Servier Valtech

Alec Vahanian,FESC, FRCP (Edin.) Bichat Hospital University Paris VII, Paris, France

Status Of The MitraClip: Trials (EVEREST II & COAPT) & FDA

Percutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives. Bernard Iung Bichat Hospital, Paris

Clinical Outcome of Tricuspid Regurgitation. David Messika-Zeitoun

Natural History and Echo Evaluation of Aortic Stenosis

Aortic Stenosis in the Elderly: Difficulties for the Clinician. Are Symptoms Due to Aortic Stenosis?

The FORMA Early Feasibility Study: 30-Day Outcomes of Transcatheter Tricuspid Valve Therapy in Patients with Severe Secondary Tricuspid Regurgitation

What is the Role of Surgical Repair in 2012

Mitral Regurgitation

Patients with severe aortic stenosis (AS), left ventricular

Aortic Regurgitation and Aortic Aneurysm - Epidemiology and Guidelines -

DECISION MAKING DEL CARDIOCHIRURGO NELL INSUFFICIENZA MITRALICA: ISTRUZIONI D USO D CARDIOLOGO

First Transfemoral Aortic Valve Implantation In Bulgaria - Crossing The Valve With The Device Is Not Always

TAVR y Enfermedad Coronaria. Mauricio G. Cohen, MD, FACC, FSCAI Director, Cardiac Catheterization Lab Associate Professor of Medicine

Percutaneous Mitral Valve Repair

Dialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy

Outline 9/17/2016. Advances in Percutaneous Mitral Valve Repair and Replacement. Scope of the Problem and Guidelines

Clinical Outcome in Patients with Aortic Stenosis

Managing the Low Output Low Gradient Aortic Stenosis Patient

Surgical AF Ablation : Lesion Sets and Energy Sources. What are the data? Steven F Bolling, MD Cardiac Surgery University of Michigan

Introducing the COAPT Trial

Corrective Surgery in Severe Heart Failure. Jon Enlow, D.O., FACS Cardiothoracic Surgeon Riverside Methodist Hospital, Ohiohealth Columbus, Ohio

The Who, How and When of Advanced Heart Failure Therapies. Disclosures. What is Advanced Heart Failure?

TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair?

Incidence And Predictors Of Left Bundle Branch Block After Transcatheter Aortic Valve Implantation

The Role of TAVI in high-risk and normal-risk Patients

Catheter-based mitral valve repair MitraClip System

Is TAVR the treatment of choice for high risk diabetic patients with aortic stenosis? Insights from the FRANCE2 Registry

Organic mitral regurgitation

Imaging in TAVI. Jeroen J Bax Dept of Cardiology Leiden Univ Medical Center The Netherlands Davos, feb 2013

Τελικά επιδιόρθωση, αντικατάσταση ή clip στην ισχαιμική ανεπάρκεια Μιτροειδούς; ΒΛΑΣΗΣ ΝΙΝΙΟΣ MD MRCP ΚΛΙΝΙΚΗ ΑΓΙΟΣ ΛΟΥΚΑΣ

Steven F Bolling Professor of Cardiac Surgery University of Michigan

Low Gradient Severe AS: Who Qualifies for TAVR? Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor

Assessing Function by Echocardiography in VHD Asymptomatic Severe Organic MR. Dr. Julien Magne, PhD Sart Tilman Liège, BELGIUM

Coronary Artery Bypass Graft: Monitoring Patients and Detecting Complications

Functional Mitral Regurgitation; therapeutic continuum overview. Michele Senni. Cardiologia 1 Scompenso e Trapianti di Cuore A.O. PAPA GIOVANNI XXIII

Objectives. Systolic Heart Failure: Definitions. Heart Failure: Historical Perspective 2/7/2009

Dr.ssa Loredana Iannetta. Centro Cardiologico Monzino

Case Report. Percutaneous Mitral Repair with MitraClip as an Adjunct Therapy of Heart Failure. Introduction. Case Report. Keywords

Indication, Timing, Assessment and Update on TAVI

Indicator Mild Moderate Severe

Overview of Surgical Approach to Mitral Valve Disease : Why Repair? Steven F. Bolling, MD Cardiac Surgery University of Michigan

Transcatheter Mitral Valve Repair and Replacement: Where is the Latest Randomized Evidence Taking US Mitral-Fr, COAPT

Mitral Gradients and Frequency of Recurrence of Mitral Regurgitation After Ring Annuloplasty for Ischemic Mitral Regurgitation

HOW IMPORTANT ARE THESE ECHO MEASUREMENTS ANYWAY?

Transcatheter Mitral Valve Repair: today and tomorrow Sponsored by Abbott. Chairperson: M. Haude Panellists: A. Al Nooryani, M.

Aortic valve replacement for severe aortic regurgitation in asymptomatic patients with normal ejection fraction and severe left ventricular dilatation

Percutaneous mitral valve repair: current techniques and results

Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing

Divisions of Cardiology and Cardiovascular Surgery, Veterans Administration Medical Center and University of Minnesota, Minneapolis, Minnesota

Gender Differences in Valvular Heart Disease. Linda D. Gillam, MD FESC Disclosure: Core Lab services Edwards Lifesciences

Degenerative Mitral Regurgitation: Etiology and Natural History of Disease and Triggers for Intervention

Risk Patients Before TAVI or AVR

Improving Quality of Care for Patients with Heart Valve Disease

Percutaneous Repair for MR:

Transcription:

Severe left ventricular dysfunction and valvular heart disease: should we operate? Laurie SOULAT DUFOUR Hôpital Saint Antoine Service de cardiologie Pr A. COHEN JESFC 16 janvier 2016

Disclosure : No conflict

1. STS National Database Risk Calculator. 2013. 2. Roques et al.j Cardiothorac Surg 1999;15:816 822. 3. Nashef et al.eur J Cardiothorac Surg 2012;41:734 744 4. Vahanian et al. European Heart Journal 2012;33:2451 2496. Background LVEF : important prognostic factor, included in current operative risk scores : STS score (1), EuroScore (2), Euroscore II (3) Clinical question remains whether it is too late to operate when the EF is severely depressed Clinical guidelines doesn t focus on this question (4) Operative mortality

Background Severe left ventricular dysfunction Medical treatment Overall mortality Valvular heart disease AR AS : low flow low gradient MR : primary/secondary Conventional surgery Percutaneous intervention Operative/ perioperative mortality Overall Mortality Symptoms : NYHA, CHF Echocardiography : LVEF

Aortic regurgitation

Severe left ventricular dysfunction and aortic regurgitation : should we operate? Vahanian et al. European Heart Journal 2012;33:2451 2496. Nishimura et al. Circulation. 2014;129:e521-e643.

Severe left ventricular dysfunction and aortic regurgitation : should we operate? Retrospective study. 450 patients / AVR for isolated AR (1980-1995) EF <35% (LoEF, n=43) / EF 35% to 50% (MedEF, n=134) /EF 50% (Nl EF, n=273). Operative mortality rate : LoEF : 14%, MedEF: 6.7%, and Nl EF: 3.7% (p=0.02). CHF after AVR EF after AVR Survival after AVR Chaliki et al. Circulation 2002;106:2687-2693

Severe left ventricular dysfunction and aortic regurgitation : should we operate? Retrospective cohort. 785 patients with severe AR. 166 patients had severe LV dysfunction (=EF 35%). 69% of these were men, age 65±16 years, and LVEF was 23±8% AVR (n=53) (32%) Clinical characteristics Survival curves in patients with EF 35% There is a clear reluctance to offer AVR in a large number of patients with severe AR associated with LV dysfunction. Kamath et al. Circulation. 2009;120:S134 S138

Aortic stenosis

Severe left ventricular dysfunction and aortic stenosis : should we operate? Vahanian et al. European Heart Journal 2012;33:2451 2496.

Severe left ventricular dysfunction and aortic stenosis: should we operate? Nishimura et al. Circulation. 2014;129:e521-e643.

Severe left ventricular dysfunction and aortic stenosis : should we operate? 2017 patients AS (AVA<1 cm², MG 40 mmhg, or IAVA<0.6 cm²/m²)/ AVR (1995 to June 2009) 4 groups : LVEF<50% in 300 [15%] patients, 50% 59% in 331 [17%], 60% 69% in 908 [45%], and 70% in 478 [24%] Overall survival as a function of LVEF. Dahl et al. Circ Cardiovasc Imaging. 2015;8:e002917

Severe left ventricular dysfunction and aortic stenosis : should we operate? Multicenter series, 217 patients (168 men, 77%) with severe AS (area <1 cm²), low EF ( 35%), and low MG ( 30 mm Hg) who AVR (1990 and 2005) NYHA functional class III or IV : pre-operatively 79%, compared with 16% after AVR (p = 0.0001). LVEF from 28±5% pre-operatively to 41±13% after AVR (p= 0.0001) Patients operated in the 1990 to 1999 era (n =112) and in the 2000 to 2005 era (n = 105) : operative mortality was lower in the recent era (10% vs. 20%, p = 0.04) 5-Year overall survival curve after RVA in the total population Levy et al. J Am Coll Cardiol 2008;51:1466 72

Severe left ventricular dysfunction and aortic stenosis : should we operate? Predictors of overall mortality In view of the very poor prognosis of unoperated patients, the current operative risk, and the long-term outcome after surgery, AVR is the treatment of choice in the majority of cases of LF/LGAS. Levy et al. J Am Coll Cardiol 2008;51:1466 72

Severe left ventricular dysfunction and aortic stenosis : should we operate? 384 patients : TAVI 2 groups: group A (50 patients) with left ventricular ejection fraction (LVEF) 35%, and group B (334 patients) with LVEF >35% Changes in LVEF In Hospital Outcome /Events Fraccaro et al. Circ Cardiovasc Interv 2012;5:253 260.

Mitral regurgitation

Severe left ventricular dysfunction and mitral regurgitation : should we operate? SMR Surgery should be considered in symptomatic patients with severe MR, LVEF <30%, option for revascularization, and evidence of viability (Iia, C) Vahanian et al. European Heart Journal 2012;33:2451 2496.

Severe left ventricular dysfunction and mitral regurgitation : should we operate? Nishimura et al. Circulation. 2014;129:e521-e643.

Severe left ventricular dysfunction and mitral regurgitation : should we operate? MIDA Registry. 1875 patients / Mitral regurgitation (flail leaflets)/ Sinus rhythm 65±13 years; median EF, 66% [60% 71%] Mitral valve surgery : 1443 patients (77%), 85% valve repair Severe LV dysfunction : EF <30% 5 patients (0.3%); 438 patients with EF of 45% to 60%, 53 patients with EF <45%. Kaplan Meier : all-cause mortality according to EF in patients under conservative management. Tribouilloy et al. Circ Cardiovasc Imaging. 2014;7:363-370.

Severe left ventricular dysfunction and mitral regurgitation : should we operate? Curves are adjusted for sex, comorbidity index, symptoms, and coronary artery disease. Outcome in EF subsets of compared between surgical and medical management. Patients with EF <45% have severe LV dysfunction, catastrophic outcome under medical management, and should not be denied surgery. Tribouilloy et al. Circ Cardiovasc Imaging. 2014;7:363-370.

Severe left ventricular dysfunction and mitral regurgitation : should we operate? Retrospective (databases from Duke University ) 1441 patients : moderate or severe functional MR + severe LV dysfunction (LVEF 30% or LV end-systolic diameter >55 mm) Baseline characteristics Samad et al. European Heart Journal 2015. 36:2733 2741

Severe left ventricular dysfunction and mitral regurgitation : should we operate? In patients with moderate or severe MR and severe LV dysfunction, mortality was substantial, and among those selected for surgery, MV surgery, though performed in a small number of patients, was independently associated with higher event-free survival. Samad et al. European Heart Journal 2015. 36:2733 2741

Severe left ventricular dysfunction and mitral regurgitation : should we operate? 59 patients with reduced EF and severe MR/ MitraClip Subgroup of patients showing severely reduced LVEF <30% (EF 23+2%; n=25) Thirty-day mortality was 2.9% Mitral valve regurgitation (MR) class NYHA functional class LA volume, LVESD,EF Percutaneous MV repair using MitraClip TM is a safe technique in high-risk surgical patients, causing significant 1 year reduction of MR which results in structural cardiac reverse remodelling and an increased LVEF. The present data encourage percutaneous MV repair in heart failure patients. Pleger et al. Eur J Heart Fail. 2013 Aug;15:919-27.

Conclusion The management of patients with severe left ventricular dysfunction and valvular heart disease is complex Cohort study/ no randomized trials Poor prognostic under medical treatment Improvement EF, NHYA after surgery Evolution of surgical therapy improvement of prognosis Patients should not be denied surgery Future : percutaneous techniques?